Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer

Yuan Dai

doi:10.47297/wspbdsWSP2752-630513.20260601

PDF
导出
分享
收藏
专辑

Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer

6卷第1期

浏览量: 0 Downloads: 0

Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer
Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer
Shandong Xiehe University, Jinan, Shandong, 250000, China
2026年6卷第1期页码：58-61
纸质出版：2026-03-30
DOI：10.47297/wspbdsWSP2752-630513.20260601
Accepted：

Scan QR Code

Yuan Dai. (2026). Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer. 生物医学大数据, 6(1), 58-61.

Yuan Dai.Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer[J].Biomedical Data Science,2026,06(01):58-61.
Yuan Dai. (2026). Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer. 生物医学大数据, 6(1), 58-61. DOI： 10.47297/wspbdsWSP2752-630513.20260601.

Yuan Dai.Mechanisms and Targeted Research Advances of the PI3K/AKT Pathway in Drug Resistance and Immune Microenvironment Regulation of HER2-Positive Breast Cancer[J].Biomedical Data Science,2026,06(01):58-61. DOI： 10.47297/wspbdsWSP2752-630513.20260601.

摘要

Abstract

HER2-positive breast cancer accounts for 20–30% of all breast cancer cases

exhibiting high invasiveness and poor prognosis. Anti-HER2 targeted therapy remains the core clinical treatment strategy; however

30–50% of patients develop primary or acquired resistance

presenting a significant therapeutic bottleneck.Abnormal activation of the PI3K/AKT pathway is a key mechanism mediating targeted resistance in this subtype of breast cancer

exhibiting close cross-regulatory interactions with the immunosuppressive state of the tumour immune microenvironment.This paper systematically reviews the regulatory mechanisms of the PI3K/AKT pathway in HER2-positive breast cancer targeted resistance

analyses its interaction patterns with the immune microenvironment

and summarises advances in combination therapy targeting this pathway. Findings indicate that the PI3K/AKT pathway synergistically mediates targeted resistance through regulating cell proliferation and immune molecule expression

leading to immune escape. - immune escape. Concurrently

combination regimens incorporating pathway inhibitors with anti-HER2 agents and immune checkpoint inhibitors demonstrate promising therapeutic potential. This study provides theoretical foundations for elucidating the nature of resistance in HER2-positive breast cancer and offers novel insights for developing personalised combination treatment strategies in clinical practice.

关键词

Keywords

references

Ai L. , & Zhang Q . Y . ( 2026 ). Research progress on drug resistance mechanisms of T-DM1 in the treatment of advanced HER2-positive breast cancer. Modern Oncology , 34 ( 02 ), 316 - 322 .

Liu G. Y. , & Wu S . Y . ( 2023 ). Transformation and future prospects of systemic therapy for early HER2-positive breast cancer. Cancer Research on Prevention and Treatment , 50 ( 05 ), 437 - 441 .

Yuan Y. X. , Nie Y. Q. , & Mu H . W . ( 2025 ). Efficacy of trastuzumab combined with chemotherapy in the treatment of HER2-positive breast cancer and its influence on immune function. Chinese Medical Innovation , 22 ( 25 ), 125 - 129 .

Chen D . ( 2021 ). Study on the expression of related molecules in trastuzumab resistance and reversal of resistance in HER2-positive breast cancer cells (Master's thesis) . Fujian Medical University .

Wu Y. , & Dai J . G . ( 2024 ). Research progress of targeted therapy for HER2-positive breast cancer. Chinese Journal of New Clinical Medicine , 17 ( 10 ), 1183 - 1186 .

Omabe M. , Ahmed S. , Sami A. , Xie Y. F. , Tao M. , & Xiang J . ( 2015 ). HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy . World Journal of Vaccines , 5 ( 2 ), 106 - 128 .

Shao J . ( 2024 ). Study on the mechanism of Circ_FAT3 regulating the PI3K/AKT pathway to inhibit the malignant biological phenotype of GBM by targeting the miR-1246/PIK3AP1 axis (Master's thesis) . Hebei University .

Pernas S. , & Tolaney S . M . ( 2019 ). HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Therapeutic Advances in Medical Oncology , 11 , 1758835919833519 .

文章被引用时，请邮件提醒。

Submit

No data

Related Author

No data

Related Institution

No data

⁰